Opportunity To Collaborate

We are looking to attract pharma or biotech partners wanting to broaden their portfolio in fibrosis.

Our first focus is systemic sclerosis interstitial lung disease (SSc-ILD), a severe, rare, chronic autoimmune disease with high morbidity and mortality.

●    High unmet need with limited treatment available
●    This disease leads to increased fibroblast activation resulting in fibrosis of the skin and internal organs, including lungs, heart, kidneys and the gastrointestinal tract
●    Scarring causes stiffness in the lungs which makes it difficult to breathe and get oxygen to the bloodstream

The secondary focus is other progressive fibrosing interstitial lung diseases, for example, IPF with positive preclinical data available. This is an area of high unmet need.

Other indications of high interest for treatment with AM1476 or related compounds include pulmonary arterial hypertension, liver fibrosis, cardiac fibrosis, fibrotic tumours as well as graft-versus-host disease.

For further information, please contact us.